[Form 4] UiPath, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 7/22/25 Unity Biotechnology (UBX) entered into a Purchase Agreement with President/Secretary and sole director Craig R. Jalbert to sell a single Series A Preferred Share for $1. The share carries 600,000,000 votes but may be used only on the forthcoming Dissolution Proposal and must mirror the proportion of votes actually cast by common shareholders. It is non-convertible, pays a $0.01 priority dividend and automatically transfers back to the company after the stockholder meeting.

The step is designed to neutralise abstentions and broker non-votes, effectively lowering the practical approval hurdle for the board-approved dissolution plan announced 6/27/25. UBX’s common stock was suspended from Nasdaq on 7/9/25 and now trades on OTC Pink (UNBX); a Form 25 will be filed to delist. The issuance was made under the §4(a)(2) private-placement exemption. This 8-K/A otherwise only adds the former address to the cover page.

Positive

• Proportional voting mechanism reduces risk that abstentions block the board-approved dissolution, providing procedural certainty.
• Automatic retirement of the Series A share after the vote prevents long-term dilution or control issues.

Negative

• Planned dissolution indicates termination of operations and uncertain recovery for shareholders.
• Nasdaq suspension and pending delisting move trading to OTC Pink, reducing liquidity and institutional interest.
• Concentration of voting power in a single insider may raise governance and fairness concerns.

Insights

Corporate Governance Analyst

TL;DR: High-vote preferred share helps ensure dissolution passes; governance and value outlook remain negative.

The issuance of a single Series A share with 600 MM votes is a classic proportional voting device that removes the blocking power of abstentions. While technically fair—because it mirrors ballots actually cast—it materially shifts the effective threshold, making it easier for management to secure stockholder approval of liquidation. Investors gain no economic benefit: the share is non-convertible, non-participating in liquidation and reverts post-vote. Combined with the recent delisting to OTC Pink, the filing underscores that UBX no longer pursues an operating strategy, only an orderly wind-down. Risk of little or no residual value remains high.

Financial Restructuring Specialist

TL;DR: Filing formalises wind-down mechanics; impact is decisive but value-destructive.

By locking in 600 MM proportional votes, the board almost guarantees approval of the pending Plan of Dissolution, accelerating the liquidation timetable. For creditors, faster execution may limit administrative burn; for equity holders, upside is capped—there are no dividend, conversion or liquidation rights attached to the preferred. The $1 issuance price and automatic retirement demonstrate the vote-only purpose. However, shifting to OTC and delisting signal diminished marketability, and liquidation usually yields cents on the dollar. I view the development as materially negative for ordinary shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dines Daniel

(Last) (First) (Middle)

C/O UIPATH, INC., ONE VANDERBILT AVENUE

60TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UiPath, Inc. [ PATH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/24/2025		S		45,000(1)	D	$12.5504(2)	4,788,376	I	See Footnote(3)
Class A Common Stock								24,918,585	D
Class A Common Stock								240,000	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold in compliance with a qualified selling plan adopted by the Reporting Person pursuant to Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.

2. The range of prices for the transactions reported was from $12.5100 to $12.6500. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.

3. The shares are held by Ice Vulcan Holding Limited. IceVulcan Investments Ltd. is the sole shareholder of Ice Vulcan Holding Limited, and Mr. Dines is the sole shareholder of IceVulcan Investments Ltd. Mr. Dines retains sole voting and investment power with respect to the shares of Class A Common Stock and Class B Common Stock held by Ice Vulcan Holding Limited.

Remarks:

	/s/ Brad Brubaker, Attorney-in-Fact	07/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Unity Biotechnology (UBX) issue only one Series A Preferred Share?

The single share carries 600 MM votes restricted to the Dissolution Proposal, ensuring votes reflect ballots actually cast and minimising abstention impact.

How will the Series A Preferred Share affect the dissolution vote for UBX?

Its 600 MM votes will be cast in the same proportion as common-stock votes, effectively lowering the practical approval threshold needed to pass dissolution.

What happens to the Series A Preferred Share after the UBX stockholder meeting?

It automatically transfers back to the company for no consideration and is retired, eliminating any ongoing voting power.

Why was UBX delisted from Nasdaq?

On 7/9/25 Nasdaq suspended trading; UBX now trades OTC Pink (UNBX). A Form 25 will formally remove the listing under Section 12(b).

Does the Series A Preferred Share receive liquidation proceeds?

No. The Certificate of Designation grants no liquidation rights; common shareholders receive any residual assets.